Canadian Stocks Have Best First Half Since Financial Crisis

The Motley Fool is a website that publishes sati At $11, is 23andMe a good buy? The consumer genetic-testing behemoth 23andMe (NASDAQ: ME) is just getting started on the NASDAQ after a business combination with VG Acquisition Corp, a special purpose acquisition company (SPAC). This stock’s growth story, in my opinion, justifies its current price, but you’ll have to keep it for a few years to see returns rise. The company’s main product, 23andMe’s direct-to-consumer health service, provides information on genetic risk factors for a variety of diseases./nRead More